Tigecycline — Better Outcomes with Higher Doses?

A phase II clinical trial involving patients with hospital-acquired pneumonia revealed a numerically higher cure rate with high-dose tigecycline than with imipenem.

Tigecycline is a glycylcycline antibiotic with a broad spectrum of antimicrobial activity that includes many multidrug-resistant pathogens. However, in September 2010, the FDA issued a drug safety warning for tigecycline because in phase III clinical trials, cure rates for serious hospital-acquired infections — particularly hospital-acquired pneumonia (HAP) — were lower among patients treated with the approved dose of tigecycline (100 mg intravenously, followed by 50 mg twice daily) than among those treated with other broad-spectrum agents such as imipenem-cilastatin (JW Infect Dis Sep 8 2010). Pharmacokinetic and pharmacodynamic analyses revealed that the mean tigecycline area under the time-concentration curve was lower in patients with v…

Reviewing Author

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection

Thomas Glück, MD

Disclosures

Editorial BoardsConsilium Infectiorum by InfectoPharm, Infection